This study compared levetiracetam (Keppra ® ) with reference antiepileptic drugs (AEDs) in the rat pilocarpine model of temporal lobe epilepsy. Electroencephalogram (EEG) recordings showed that i.p. administration of valproate (300 mg/kg), phenobarbital (5 mg/kg) and clonazepam (0.5 mg/kg) all significantly delayed the appearance of the first epileptic spike discharge in hippocampus as well as synchronous epileptiform activity in hippocampus and cortex. In contrast, i.p. administration of levetiracetam (17 mg/kg) only significantly delayed the appearance of the latter. This was corroborated by findings showing that i.p. administration of levetiracetam (17 mg/kg) significantly opposed pilocarpine-induced increases in the amplitude of the orthodromic population spike in the hippocampal CA3 area of urethane-anaesthetised rats, while valproate (200 mg/kg), phenobarbital (10 mg/kg) and clonazepam (1 mg/kg) had no effect. Pre-treatment i.p. with phenobarbital (10 mg/kg) and clonazepam (0.5 mg/kg) significantly reversed seizure-induced changes in aspartate and GABA concentrations while valproate (300 mg/kg) significantly reduced aspartate concentrations further. In contrast, levetiracetam (34 mg/kg) significantly counteracted all seizure-induced alterations in amino acid concentrations. Midazolam induced significant seizure protection after microinjection into substantia nigra pars reticulata (SNR, 50 nmol), nucleus accumbens (NA, 25 nmol) and caudate putamen (CP, 25 nmol), whereas phenytoin (50 nmol) only showed significant seizure protection after injection into the latter area. Levetiracetam differed by significant seizure protection after injection into SNR (1000 nmol) and NA (3000 nmol). These results suggest that levetiracetam is distinct from other AEDs by its ability to selectively suppress synchronisation of neuronal spike and burst firing in hippocampus.
INTRODUCTION
Seizures induced by systemic administration of pilocarpine to rats have a focal limbic onset, and thereby mimic complex partial seizures with secondary generalisation in man 1 . Systemic administration of GABAergic antiepileptic drugs (AEDs) (benzodiazepines and barbiturates) suppress seizures in this model 2 . Blockers of Na + channels (carbamazepine and phenytoin) are inactive and the T-type Ca 2+ channel blocker ethosuximide increases the susceptibility to these seizures. The same profile is observed after intranigral microinjection 3 and correlates with the ability of these drugs to alter firing in GABAergic neurones in substantia nigra pars reticulata (SNR) 4 . This suggests a selective action of GABAergic drugs in this model involving an ability to directly suppress neuronal activity in the GABAergic projections from SNR.
Levetiracetam (LEV; Keppra ® ) is a novel AED that previously has been reported to suppress pilocarpine-induced seizures in both mice and rats after systemic administration 5 . The mechanism of action of LEV appears unrelated to any modulation of voltage-activated Na + and low-voltage-activated (T-type) Ca 2+ channels 6 . A substantial number of studies have also reported that LEV is devoid of any conventional effects on the GABAergic system [7] [8] [9] [10] .
Instead, LEV appears associated with several novel mechanisms involving a moderate reduction in the high-voltage-activated Ca 2+ current 11 and a modest, partial inhibition of the delayed rectifier K + current 12 .
Another effect may relate to an ability to oppose the inhibitory action of several negative allosteric modulators on ionotropic inhibitory receptors 9 .
The ability of LEV to suppress pilocarpine-induced seizures in both mice and rats appears to contrast the lack of evidence for any direct facilitation of GABAergic inhibition. This stimulated the present study to characterise electrophysiological and neurochemical effects of LEV on main excitatory and inhibitory neurotransmitters in the rat pilocarpine model and to compare with the action of GABAergic AEDs. Another part of this study was devoted to identify brain areas involved in LEV's seizure protection and to compare with the profile of classical AEDs having either GABAergic or Na + channel blocking effects.
MATERIAL AND METHODS

Animals
Adult male Sprague-Dawley rats weighing 300-350 g were used. The animals were kept on a 12/12 hour light/dark cycle with light on at 06:00 hour and were housed at a temperature maintained at 20-21 • C and at a humidity of about 40%. All animals had free access to standard pellet food and water before random assignment to experimental groups.
Pilocarpine-induced seizure activity
The rats were pre-treated with methyl-bromoscopolamine (1 mg/kg s.c.) 30 minutes before administration of pilocarpine. The dose of pilocarpine selected (375 mg/kg i.p.) was a CD 97 dose for the induction of secondarily generalised seizures (stage 3, 4 and 5 seizures, see the following description) in 97% of the animals 5 . After administration of pilocarpine, the convulsive behaviour was scored in experiments involving awake animals according to Racine 13 where 0 = no reaction; 1 = stereotype mouthing, eye blinking and/or mild facial clonus; 2 = head nodding and/or severe facial clonus; 3 = myoclonic jerks in the forelimbs; 4 = clonic convulsions in the forelimbs with rearing and 5 = generalised clonic convulsions associated with loss of balance.
Electroencephalogram (EEG) recordings
The animals were implanted with an electrode in right hippocampus and three cortical electrodes (frontal left and occipital right and left). The AEDs were administered i.p. at optimal pre-treatment times at their minimum active dose against secondarily generalised motor seizures induced by pilocarpine in rats (LEV at 17 mg/kg i.p. −60 minutes; valproate at 300 mg/kg i.p. −15 minutes; clonazepam at 0.5 mg/kg i.p. −30 minutes; phenobarbital at 5 mg/kg i.p. −30 minutes) 5 . Immediately after pilocarpine administration, EEG recordings were started and performed for 120 minutes. The time to onset of the first isolated spike and burst discharge in hippocampus, the first three synchronous episodes of a fluctuating signal (waxing and waning) in hippocampus together with an isoelectric signal in cortex and the first burst of at least 4 seconds with a minimum frequency of 8 Hz in both hippocampus and cortex were determined (Fig. 1) .
Extracellular field potentials in the hippocampal CA3 area
Our methodology of extracellularly recording field potentials in the hippocampal CA3 area of urethaneanaesthetised rats has previously been described 14 . The characteristic field potential, elicited in the CA3 area by commissural stimulation, is known 15 to consist of two population spikes (PS): a shorter latency antidromic (i.e. non-synaptic) PS anti and a longer (>3 ms) latency orthodromic PS ortho (see example of response in Fig. 2 ). Evoked field potentials were recorded before the injection of pilocarpine and then repeated three times, starting at 30, 60 and 100 minutes after pilocarpine administration. The acquisition software averaged on-line three successive samples of field potentials, evoked at 20-second intervals, and calculated the amplitudes (and latencies) of PS. The amplitude of each PS was measured from the negative peak to a tangent drawn between the preceding and the following maxima of the waveform. The response of each animal was consistently expressed by the amplitude of the orthodromic (i.e. trans-synaptic) PS, Ps ortho , elicited with stimuli of 1 mA.
Amino acid concentrations in hippocampus
Immediately following pilocarpine administration, motor seizures were observed. Groups of rats were decapitated after 15 minutes with partial (focal) seizures, other groups after partial seizures followed by secondary generalisation for 30 minutes. Hippocampus were removed on an ice-chilled plate, frozen in liquid nitrogen and weighed. Tissue was homogenised in a 0.1 mol/l solution of HClO 4 containing EDTA 300 µmol/l and heparin (150 IU/ml) in a proportion of 8 µl/mg tissue. The samples were then centrifuged at 1200 × g (4 • C) for 15 minutes. The supernatant was used for HPLC determination of amino acids known to act as main excitatory (aspartate) or inhibitory (glycine, GABA) neurotransmitters or to be involved in the metabolism of the latter (glutamine) using fluorescence detection following precolumn derivatisation (AccQ.Tag Method-Waters). 
Microinjection of AEDs into specific brain areas
Infusions were performed bilaterally in unanaesthetised rats 12-14 days after implantation of guide cannulas. The drugs were delivered in a volume of 1 µl at a rate of 0.5 µl/minute to SNR, caudate putamen (CP) and nucleus accumbens (NA). Fifteen minutes prior to pilocarpine administration, LEV (10 nmol-3 µmol), midazolam (10-50 nmol) or phenytoin (10-50 nmol) were microinfused for 2 minutes. After observation for the motor seizures, the brain of the animals were removed and histologically examined for correct implantation.
Drugs
LEV was synthesised in the chemical laboratories of UCB. Together with pilocarpine hydrochloride (Sigma), methyl-bromoscopolamine (Sigma), sodium valproate (Sigma), midazolam (Hoffman-La Roche), Values given are median, 1st and 3rd quartiles (N = 6). Asterisks ( * ) and ( * * ) indicate significant statistical difference compared to the control group of P < 0.05 and P < 0.01, respectively. sodium phenobarbital (Federa) and sodium phenytoin (RBI), all these compounds were dissolved in 0.9% saline. Clonazepam (Hoffman-La Roche) was suspended in 0.9% saline containing 0.1% Tween 80.
Statistical analysis
A Kolmogorov-Smirnov test was applied for determining the significance of differences on EEG parameters between control and treated groups. A paired t-test was used for determining the significance of time-related changes in pilocarpine-induced alterations in the amplitude of PS ortho within both the control and treated groups, whereas comparisons between control and treated groups were performed with an unpaired t-test. An unpaired t-test was also applied for determining the significance of differences in alterations in amino acid concentrations in hippocampus, both with respect to comparisons between control, partial and generalised seizure groups as well as with respect to comparisons between control and treated groups. A Fisher test (one tailed) was applied for determining the significance of difference between control and treated groups in the percentage of animals showing secondarily generalised seizures after microinfusion into specific brain areas. In all experiments, differences were considered statistically significant when P < 0.05.
RESULTS
EEG recordings
Valproate, clonazepam and phenobarbital all significantly delayed both the appearance of the first epileptic spike discharge in hippocampus and synchronous epileptiform activity (waxing and waning, isoelectric signal and burst firing) in hippocampus and cortex (Table 1 ). In contrast, LEV only significantly delayed the appearance of the latter.
Extracellular field potentials in the hippocampal CA3 area
Pilocarpine increased the amplitude of PS ortho , evoked in CA3 area by constant-current commissural stimulation, in a time-dependent manner (Fig. 2) . Pilocarpine-induced increase in PS ortho amplitude was nearly eliminated by pre-administration of LEV (Fig. 3) . The data in Table 2 show that the pilocarpine-induced increase in PS ortho amplitude was significantly lower in the group pre-treated with LEV. In contrast, only a trend was observed with clonazepam, and valproate and phenobarbital had no effect.
Amino acid concentrations in hippocampus
Secondary generalised seizures generally induced more marked alterations in the amino acid concentrations of excitatory and inhibitory neurotransmitters than partial seizures (Fig. 4 ). Significant reductions in aspartate and increases in glutamine and GABA levels were observed. In contrast, glycine levels remained unchanged. Treatment with phenobarbital and clonazepam significantly reversed the changes in aspartate and GABA levels (increase in aspartate and reduction in GABA) observed after pilocarpine-induced secondary The values, expressed in mV, represent mean ± SD (N = 6 rats per group) of the differences between the amplitude of PS ortho , measured in the same animal at different times after pilocarpine 375 mg/kg i.p. (PILO) and the amplitude measured before PILO. Significant (P < 0.05) differences between the treated group and the paired control group, assessed with t-test, are indicated with asterisk ( * ).
generalised seizures whereas valproate only revealed a significant ability to further reduce aspartate levels (Fig. 5) . In contrast, LEV significantly reversed all alterations induced by secondary generalised seizures by increasing aspartate and reducing glutamine and GABA levels. In addition, a minor, but significant, reduction was also observed in the glycine levels that was unaffected by the pilocarpine-induced secondary generalised seizures.
Microinjection of AEDs into specific brain areas
Midazolam protected significantly against secondarily generalised seizures induced by pilocarpine after infusion into both SNR, CP and NA (Table 3) . Phenytoin only showed significant seizure suppression after infusion into CP. In contrast, LEV revealed significant seizure protection after infusion into SNR and NA.
DISCUSSION
The CA3 area has been known for long to be the hippocampal region where epileptiform bursting originates 16 . The pilocarpine-induced increase in the amplitude of the orthodromic PS in this brain region indicates that pilocarpine entailed a larger number of neurones to fire simultaneously (neuronal synchrony). Our results suggest that LEV opposes this increase in neuronal synchrony in the hippocampus. This corroborates previous in vitro 17 and in vivo 14 observations showing that LEV reduces epileptiform increases in the PS amplitude in other rat models of epilepsy. In contrast, clonazepam only revealed a trend to oppose this marker of the epileptiform effect of pilocarpine, and valproate and phenobarbital did not oppose it at all. EEG analysis of seizures induced by systemic administration of pilocarpine to rats suggests a hippocampal origin of epileptic activity, starting with isolated neuronal spike discharges which progresses into burst firing that finally increases in intensity and then propagates to cortex 1 . Pre-treatment with LEV and GABAergic AEDs in comparative doses, i.e. the lowest effective dose giving a significant protection against secondary generalised seizures 5 , revealed a particular type of electrographic action of LEV against pilocarpine-induced seizures. In contrast to the effect of GABAergic AEDs, LEV did not interfere with the onset of neuronal spike and burst firing in hippocampus, but inhibited sufficient synchronisation for their propagation to cortex. Likewise, LEV opposed the neuronal synchronisation reflected in the pilocarpine-induced increase in the amplitude of the orthodromic PS in CA3, while the GABAergic AEDs were inactive. It should be noted that the experimental conditions of the EEG and extracellular field potential recordings differ markedly by the former being conducted in awake and the latter in urethane-anaesthetised rats. This prevents any direct comparison of similar dose levels. Despite this limitation, the findings in both models suggest that the observed inhibition by LEV of seizure propagation from hippocampus to cortex relates to an interference with synchronisation of epileptiform activity. Thus, the seizure protection afforded by LEV against pilocarpine-induced secondary generalised motor seizures may involve a selective ability to prevent synchronisation of neuronal discharges deriving from hippocampus and thereby their propagation to cortex.
These findings confirm previous in vitro 18 and in vivo 19 recordings from the CA3 hippocampal area showing that LEV interferes with neuronal burst firing induced by synaptic activation in the presence of the chemoconvulsant bicuculline, without altering normal neuronal excitability. Indeed, a recent in vitro study on epileptiform responses induced by a 'high K + -low Ca 2+ ' perfusion fluid in the CA3 hippocampal area of slices suggested that LEV is distinct from classical AEDs by its ability to inhibit neuronal hypersynchronisation 17 . This selective ability of LEV to prevent synchronisation of neuronal spike and burst firing without affecting normal neuronal excitability may also explain both its lack of anticonvulsant activity against acute seizures with immediate ictal activity induced by a maximal electroshock or maximal CD 97 doses of different chemoconvulsants, as well as its significant safety margin in rodents 5 .
The pattern of pilocarpine-induced alterations in hippocampal amino acid concentrations of known excitatory and inhibitory neurotransmitters observed in the present study confirms previous reports 20, 21 . Although the pharmacological effect of the AEDs in general was modest, LEV, phenobarbital and clonazepam appear to contrast valproate in their action against pilocarpine-induced alterations in amino acid concentrations. Indeed, these three AEDs induced a similar pattern consisting of elevation of aspartate levels and reductions in GABA levels. Likewise, LEV also significantly reduced the enhanced glutamine levels following pilocarpine-induced seizures. Taken together, these results suggest that LEV induced a more marked normalisation of pilocarpine-induced changes in hippocampal concentrations of neurotransmitters than other AEDs which may be associated to phenobarbital (PB; 10 mg/kg i.p. 30 minutes before PILO, N = 9); controls (N = 9) to clonazepam (CZP; 0.5 mg/kg i.p. 30 minutes before PILO, N = 13) and controls (N = 13) to valproate (VAL; 300 mg/kg i.p. 15 minutes before PILO, N = 14). Significant differences (P < 0.05, P < 0.01, P < 0.001) with respect to the control group, assessed with a t-test, are indicated with asterisks ( * ), ( * * ) and ( * * * ), respectively.
with its ability to counteract synchronisation of neuronal spike and burst firing in hippocampus.
Systemic administration of pilocarpine to rats induces motor seizures which are selectively suppressed by systemic and intranigral injection of AEDs which modulate GABAergic neurotransmission 3 . Although there is no consistent evidence to support direct effect on the GABA system, LEV also protects against these seizures after both systemic and intranigral injection. This is consistent with a recent report showing that LEV reduces spontaneous neuronal firing in SNR of anaesthetised rats after systemic administration 22 . The same paper suggested that marked reductions in striatal GABA turnover induced by LEV disinhibits the GABAergic pathway from striatum to SNR sufficiently to induce significant reductions in the neuronal activity of the GABAergic projections from the SNR. Indeed, it has been proposed that a deficit in GABA-mediated inhibition in the striatum disinhibits GABAergic striatal output pathways to SNR and thereby enhances inhibition in SNR and propagation of seizure activity 22 . Interestingly, the present study showed that direct microinjection of LEV into the SNR also induces seizure protection. This suggests that LEV might reduce SNR neuronal firing by both indirect and direct effects.
Our findings revealed an area-specific action of LEV against pilocarpine-induced motor seizures that appears to differ both from that of benzodiazepine ligands (midazolam) and from that of Na + channel Compounds were microinfused 15 minutes prior to pilocarpine administration and the rats were scored for severity of motor seizures during 2 hours. Values given are the percentage of animals showing secondarily generalised seizures (N = 4-10 per group). Significant (P < 0.05) differences with respect to the control group, assessed with a Fisher test, are indicated with asterisk ( * ).
blockers (phenytoin). In that respect, the seizure protection of LEV after infusion into a sub-area of striatum (NA) is interesting. Several studies have reported that focal injection of various non-GABAergic ligands into striatum induces protection against pilocarpine-induced motor seizures in rats [23] [24] [25] . This suggests that the modulation by LEV in situ of neuronal firing in GABAergic projections from the SNR partly may involve activation or inhibition of neurotransmitter systems deriving from other brain areas than the SNR, in particular from striatum, and partly from a direct action on SNR. In summary, the present study demonstrates that the seizure protection afforded by systemic administration of LEV against pilocarpine-induced motor seizures in rats is distinct from GABAergic AEDs by involving a selective inhibition of synchronisation of neuronal spike and burst firing in the hippocampus. This may relate to an ability to reverse pilocarpine-induced alterations in hippocampal concentrations of aspartate, glutamine and GABA as well as to a reduction in glycine levels, the latter being unaffected by seizure activity. Like GABAergic drugs, LEV induced seizure suppression after intranigral injection but revealed an area-specific seizure protection which differs from both GABAergic and Na + channel blocking AEDs. Taken together, these results suggest a novel mode of action of LEV in the rat pilocarpine model of temporal lobe epilepsy.
